

Neuroprotective effect of DL-3-n-butylphthalide against ischemia-reperfusion injury is mediated by ferroptosis regulation via the SLC7A11/GSH/GPX4 pathway and the attenuation of blood-brain barrier disruption

Shuangli Xu¹, Xuewei Li², Yutian Li³, Xiangling Li⁴, E Lv⁵, Xiaojun Zhang², Youkui Shi^{1*}, Yanqiang Wang^{2*}

¹Emergency Department, the Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China

²Department II of Neurology, the Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China

³School of Pharmacy, Weifang Medical University, Weifang, Shandong, China.

⁴Department of Internal Medicine, the Affiliated Hospital of Weifang Medical University, Weifang, Shandong, China

⁵Department of Histology and Embryology, Weifang Medical University, Weifang, Shandong, China.

***Correspondence:**


Youkui Shi

E-mail: syk2101603@163.com



Yanqiang Wang

E-mail: wffywyq2006@126.com or wangqiangdoctor@126.com


Running title: The neuroprotective effect of DL-3-n-butylphthalide




Supplementary Figure 1. The histopathological and structural changes by HE, Nissl staining. (A) HE staining, x200. (B) Nissl staining, x200.



Supplementary Figure 2. The occludin tight junction protein of BBB. (A) The expression of occludin. (B) The qualification of occludin. BBB, the blood-brain barrier. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. The values represent the mean \pm SD, $n = 3$.




Supplementary Figure 3. Co-immunostaining ZO-1 with CD31 could detect the integrity of the tight junction of the BBB better. The density of luminous dots is observed from immunofluorescence staining. The immunofluorescence double-label CD31 with ZO-1.




Supplementary Figure 4. Co-immunostaining occludin with CD31 could detect the integrity of the tight junction of the BBB better. The density of luminous dots is observed from immunofluorescence staining. The immunofluorescence double-label CD31 with occludin.

(A)



(B)



Supplementary Figure 5. (A) The qualification of CD31-positive and ZO-1-positive cells in each group. (B) The qualification of CD31-positive and occludin-positive cells in each group. ##, $p < 0.001$ (Sham vs MCAO/R); ###, $p < 0.001$ (MCAO/R vs MCAO/R+NBP-M); &, $p < 0.05$ (MCAO/R vs MCAO/R+NBP-L); &&, $p < 0.001$ (MCAO/R vs MCAO/R+NBP-M); &&&, $p < 0.001$ (Sham vs MCAO/R); p *, $p < 0.05$; ***, $p < 0.001$. Data are presented as the mean \pm SD, n = 3.

https://www.jianguoyun.com/p/DbXtNOYQn_jrChiQ6NAEIAA

The original data has been shown in JIANGUOYUN.